

Nasal colonization of SCCmec II, III and *tst*-I positive Methicillin resistance Staphylococcal aureus isolated from patients in a hemodialysis unit, Tehran, Iran

Abstract

Patients with end-stage renal disease undergoing dialysis are at the high risk of infections or colonization with MRSA. We evaluated the status colonization of two hemodialysis patients and determined their phenotype by using oxacillin and cefoxitin disks and also studied their genotypes by using PCR. We found the MRSA strains in our cases were healthcare associated harboring SCCmec II & III and *tst* or PVL gene positive. This report emphasizes the importance of *S. aureus* status colonization in this group due to MSSA and MRSA isolates can harbor the mobile genetic element of *tst* gene and also the acquisition of the SCCmec for changing MSSA to MRSA is possible.

Keywords: *Staphylococcus aureus*, Hemodialysis, SCCmec, *mecA*, *tst* gene, PVL, exfoliative gene

Volume 7 Issue 1 - 2019

Zohreh Aminzadeh,¹ Atefeh Akhavi Mirab,¹
Mehdi Goudarzi,² Narges sadat Zahed³

¹Infectious Disease and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Iran

²Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Iran

³Department of Nephrology, Shahid Beheshti University of Medical Sciences, Iran

Correspondence: Zohreh Aminzadeh, Infectious Disease and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
Email: zohrehaminzadeh@yahoo.com

Received: January 25, 2019 | **Published:** February 26, 2019

Introduction

Infections due to *Staphylococcus aureus* account for a major cause of morbidity and mortality in hemodialysis patients.^{1,2} Colonization of *S. aureus* is associated with a four-fold higher risk of bloodstream infection. Hemodialysis patients suffer from a high rate of infection or colonization with MRSA which lead to increased rate of mortality, length of hospital stay, and healthcare costs compared to those infected with methicillin-susceptible *S. aureus*.^{3,4} Methicillin susceptible *S. aureus* changes to MRSA by acquisition of staphylococcal Cassette Chromosome *mec* (SCCmec) a genomic island that encodes methicillin resistance.⁵ The *tst* gene, a mobile genetic element, encodes Toxic shock syndrome toxin 1 (TSST-1) a super-antigenic toxin secreted by both MRSA and MSSA.⁶ Besides, Panton-Valentine leukocidin is a gamma-toxin mostly produced by CA-MRSA.⁷ The aim was to determine the presence of *mecA*, *lukS/lukF-PV* (PVL), *eta* & *etb* genes (exfoliative toxin A & B) and *tst* genes (TSST-1) in two *S. aureus* colonized patients.

Material and methods

Following our previous research regarding nasal carriage of *S. aureus* in hemodialysis units,⁸ we re-evaluated two of those patients who were colonized with MRSA in the last time and at the time of re-evaluation in order to determine the presence of *mecA*, *lukS/lukF-PV* (PVL), *eta* & *etb* genes (exfoliative toxin A & B) and *tst* genes (TSST-1) by PCR. All *mecA*-positive isolates were classified to staphylococcal cassette chromosome *mec* (SCCmec) types by multiplex PCR.

Bacterial strains

The nasal samples of patients were cultured in blood agar and mannitol salt agar medium, and identification of *S. aureus* was done using Gram staining and conventional biochemical tests.⁹ Finally, the isolates were stored in tryptic soy broth containing 15% glycerol, and stored at -70°C until future processing.

Phenotypic determination of MRSA

The disk diffusion method was used for the phenotypic detection of MRSA. The oxacillin (OX) and cefoxitin (FOX) discs on Mueller-Hinton agar plates containing 4% NaCl were used. A zone of inhibition of < 21mm for oxacillin and <13mm for cefoxitin were considered MRSA (10). *Staphylococcus aureus* ATCC700698 was used as the positive control for MRSA strains.¹¹

DNA extraction and polymerase chain reaction

Genomic DNA of MRSA strains were extracted using the commercial kit InstaGene Matrix (BioRad; USA) with the addition of lysostaphin (Sigma-Aldrich; USA) to a final concentration of 15µg/ml. Then, the concentration of DNA was assessed using a spectrophotometer. Genomic DNA was extracted using a commercially available DNA extraction kit (QiaAmp DNA Mini Kit) based on the manufacturer's instructions. For confirmation of MRSA, the *mecA* gene was detected by PCR with the specific primers listed in the Table.¹² *Staphylococcus aureus* ATCC700698 was used as the positive control for *mecA* gene detection.¹¹

SCCmec typing

SCCmec typing was performed for all MRSA isolates by multiplex PCR. Primer sequences have been demonstrated in the Table 1. SCCmec types were identified by comparing the banding patterns of MRSA to ATCC 10442 (SCCmec type I), N315 (SCCmec type II), 85/2082 (SCCmec type III), MW2 (SCCmec type IV), WIS (SCCmec type V) as reference strains.

Case I

A 59-year old man was on maintenance hemodialysis for 1.2 year. He has used a fistula as his venous access and suffering from the co-morbidities of diabetes mellitus and hypertension. He did not have a history of admission, surgery, skin and soft tissue infections or taking antibiotics over the previous three months. His MRSA isolate

harbored *mecA* gene, SCCmec type III and *tst* gene but was negative for exfoliative toxins (*eta* & *etb*) and PVL.

Case 2

A 58-year-old man was on maintenance hemodialysis for 2.5 years. He had a fistula as his venous access and was suffering from diabetes

mellitus and heart failure. His past medical history included taking antibiotics over the previous three months with no hospitalization, surgery or skin and soft tissue infections. The isolated MRSA harbored PVL, *mecA* gene and SCCmec type II. The isolate was not producing exfoliative toxin A and B and TSST-1. The Table 1 shows the Oligonucleotide primers, and the characteristic information of our patients.

Table 1 The oligonucleotide primers and characteristic information, A hemodialysis unit, Tehran, Iran

| Target | Primer | Primer sequence (5' → 3') | Product Size | Reference | Case1 | Case2 |
|--------|----------|---------------------------------|--------------|-----------|----------|----------|
| mecA | F | AGAAGATGGTATGTGGAAGTTAG | 583 | 12 | Positive | Positive |
| | R | ATGTATGTGCGATTGTATTGC | | | | |
| luk-PV | F | TTCACTATTGTAAAAGTGTGACACCCACT | 180 | 13 | Negative | Positive |
| | R | TACTAATGAATTTTTTATCGTAAAGCCCTT | | | | |
| tst-1 | F | TTATCGTAAGCCCTTTGTTG | 398 | 12 | Positive | Negative |
| | R | TAAAGGTAGTTCTATTGGAGTAGG | | | | |
| eta | F | GCAGGTGTTGATTTAGCATT | 93 | 14 | Negative | Negative |
| | R | AGATGTCCCTATTTTTGCTG | | | | |
| etb | F | ACAAGCAAAGAATACAGCG | 226 | 14 | Negative | Negative |
| | R | GTTTTGGCTGCTTCTCTTG | | | | |
| SCCmec | Fβ | ATTGCCTTGATAATAGCCYTCT | 937 | 15 | Positive | |
| | R α3 | TAAAGGCATCAATGCACAAACACT | | | | |
| | F ccrC | CGTCTATTACAAGATGTTAAGGATAAT | 518 | 16 | | |
| | R ccrC | CCTTTATAGACTGGATTATTCAAATAT | | | | |
| SCCmec | F 1272 | GCCACTCATAACATATGGAA | 415 | 15-17 | | |
| | R 1272 | CATCCGAGTGAAACCCAAA | | | | |
| SCCmec | F 5RmecA | TATACCAAACCCGACAACACTAC | 359 | 16-17 | | |
| | R 5R431 | CGGCTACAGTGATAACATCC | | | | |
| SCCmec | F | ATCATTAGGTAAAATGTCTGGACATGATCCA | 433 | 13 | | |
| | R | GCATCAAGTGATTGGATAGCAAAAAGC | | | | |

Discussion

The isolated MRSA of our patients harbored SCCmec II & III which as expected. The MRSA infections in hemodialysis patients were conventionally considered to be acquired from healthcare (HA), usually with strains harboring SCCmec types II/III.¹⁸ Moreover, both MRSA clones in our patients were in agreement with the geographic distribution and pattern of MRSA clones in Asian countries.¹⁹ Besides, one of our cases was colonized with MRSA harboring PVL and SCCmec II. In other research, many CA-MRSA isolates harbored PVL gene⁷ and CA-MRSA harboring SCCmec IV & V was associated with PVL gene carriage.²⁰ Therefore, it seems our clone was HA-MRSA harboring PVL gene.

The MRSA isolated from the case 1 in present study harbored *tst-I* gene. The *tst* gene was identified among MSSA and MRSA^{21,22} and also was detected in both CA-S.aureus and HA-S.aureus.²³ The *tst*-positive strains usually spread silently in hospitals and do not always lead up to clinical symptoms.²⁴ However, in an in-vitro study, one strain of MRSA which was isolated from a hemodialysis patient with the catheter-related infection could have expressed the *tst* gene.²⁵ Besides, nasal colonization of healthcare workers with TSST-1

positive S.aureus was reported²⁶ and MRSA harboring *tst-I* gene was known as an endemic pathogen in the hospital.²⁷ We think the isolated *tst*-positive MRSA in our patient was HA-MRSA.

The MRSA colonized in the case I had SCCmec III and *tst* gene. A higher mortality rate in patients with *tst-I* positive or SCCmec II MRSA isolates was reported.²⁸ It seems harboring *tst* gene in case of clinical symptoms would be associated with a poor prognosis. However, none of the *tst*-positive S.aureus strains was positive for PVL in previous reports²⁹ that is similar to present report.

Conclusion

Because both MSSA and MRSA isolates can harbor the mobile genetic element of *tst* gene and also the acquisition of the SCCmec for changing MSSA to MRSA is possible, this study has emphasized that how important is to evaluate and detect the colonization status of hemodialysis patients for S.aureus regardless of the resistant pattern.

Acknowledgments

None.

Conflicts of interest

Authors declare that there is no conflicts of interest.

References

1. Nouwen JL, Fieren MW, Snijders S, et al. Persistent (not intermittent) nasal carriage of *Staphylococcus aureus* is the determinant of CPD-related infections. *Kidney Int.* 2005;67(3):1084–1092.
2. Worth LJ, Spelman T, Holt SG, et al. Epidemiology of infections and antimicrobial use in Australian haemodialysis outpatients: findings from a Victorian surveillance network, 2008-2015. *J Hosp Infect.* 2017;97(1):93–98.
3. Shinefield H, Black S, Fattom A, et al. Use of a *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis. *N Engl J Med.* 2002;346(7):491–496.
4. Yu VL, Goetz A, Wagener M, et al. *Staphylococcus aureus* nasal carriage and infection in patients on hemodialysis. *N Engl J Med.* 1986;315(2):91–96.
5. Ito T, Kuwahara K, Hiramatsu K. Staphylococcal cassette chromosome *mec* (SCC *mec*) analysis of MRSA. *Methods Mol Biol.* 2014;1085:131–148.
6. Novick RP. Mobile genetic elements and bacterial toxinoses: the superantigen-encoding pathogenicity islands of *Staphylococcus aureus*. *Plasmid.* 2003;49(2):93–105.
7. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant *Staphylococcus aureus*: the role of Panton–Valentine leukocidin. *Lab Invest.* 2007;87(1):3–9.
8. Zahed NS, Aminzadeh Z, Akhavi Mirab AS, et al. Nasal and Extra nasal methicillin resistant staphylococcus aureus colonization among hemodialysis patients; is routine culturing of other body sites necessary? *Journal Renal Injury prevention.* 2018;7(4):280–285.
9. Kali A, Stephen S, Umadevi S. Laboratory evaluation of phenotypic detection methods of methicillin-resistant *Staphylococcus aureus*. *Biomed J.* 2014;37(6):411–414.
10. *M100-s24 performance standards for antimicrobial susceptibility testing.* Wayne: Clinical and laboratory standards institute; 2014.
11. Martineau F, Picard FJ, Roy PH, et al. Species-specific and ubiquitous-DNA-based assays for rapid identification of *Staphylococcus aureus*. *J Clin Microbiol.* 1998;36(3):618–623.
12. Dibah S, Arzanlou M, Jannati E, et al. Prevalence and antimicrobial resistance pattern of methicillin resistant *Staphylococcus aureus* (MRSA) strains isolated from clinical specimens in Ardabil, Iran. *Iran J Microbiol.* 2014;6(3):163–168.
13. Jarraud S, Mougél C, Thioulouse J, et al. Relationships between *Staphylococcus aureus* genetic background, virulence factors, agr groups (alleles), and human disease. *Infect Immun.* 2002;70(2):631–641.
14. Alfatemi SM, Motamedifar M, Hadi N, et al. Analysis of virulence genes among methicillin resistant *Staphylococcus aureus* (MRSA) strains. *Jundishapur J Microbiol.* 2014;7(6):e10741.
15. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome *mec* integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 2001;45(5):1323–1336.
16. Ito T, Ma XX, Takeuchi F, et al. Novel type V staphylococcal cassette chromosome *mec* driven by a novel cassette chromosome recombinase, *ccrC*. *Antimicrob Agents Chemother.* 2004;48(7):2637–2651.
17. Boye K, Bartels MD, Andersen IS, et al. A new multiplex PCR for easy screening of methicillin-resistant *Staphylococcus aureus* SCCmec types I–V. *Clin Microbiol Infect.* 2007;13(7):725–727.
18. Johnson LB, Jose J, Yousif F, et al. Prevalence of colonization with community-associated methicillin-resistant *Staphylococcus aureus* among end-stage renal disease patients and healthcare workers. *Infection Control & Hospital Epidemiology.* 2009;30(1):4–8.
19. Ko KS, Lee JY, Suh JY, et al. Distribution of major genotypes among methicillin-resistant *Staphylococcus aureus* clones in Asian countries. *J Clin Microbiol.* 2005;43(1):421–426.
20. Dhawan B, Rao C, Udo EE, et al. Dissemination of methicillin-resistant *Staphylococcus aureus* SCCmec type IV and SCCmec type V epidemic clones in a tertiary hospital: challenge to infection control. *Epidemiol Infect.* 2015;143(2):343–353.
21. Papadimitriou-Olivgeris M, Drougka E, Fligou F, et al. Spread of Tst–Positive *Staphylococcus aureus* Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units. *Toxins.* 2017;9(9):E270.
22. Hu DL, Omoe K, Inoue F, et al. Comparative prevalence of superantigenic toxin genes in methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* isolates. *J Med Microbiol.* 2008;57(9):1106–1112.
23. Deurenberg RH, Nieuwenhuis RF, Driessen C, et al. The prevalence of the *Staphylococcus aureus* *tst* gene among community- and hospital-acquired strains and isolates from Wegener’s Granulomatosis patients. *FEMS Microbiol Lett.* 2005;245(1):185–189.
24. Argudín MA, Argumosa V, Mendoza MC, et al. Population structure and exotoxin gene content of methicillin-susceptible *Staphylococcus aureus* from Spanish healthy carriers. *Microb Pathog.* 2013;54:26–33.
25. Paniagua-Contreras GL, Monroy-Pérez E, Vaca-Paniagua F, et al. Expression of enterotoxin-coding genes in methicillin-resistant *Staphylococcus aureus* strains isolated from Mexican haemodialysis patients. *Ann Clin Microbiol Antimicrob.* 2014;13:55.
26. Hogan B, Rakotozandrindrainy R, Al-Emran H, et al. Prevalence of nasal colonisation by methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* among healthcare workers and students in Madagascar. *BMC Infect Dis.* 2016;16(1):420.
27. Al Laham N, Mediavilla JR, Chen L, et al. MRSA clonal complex 22 strains harboring toxic shock syndrome toxin (TSST-1) are endemic in the primary hospital in Gaza, Palestine. *PLoS One.* 2015;10(3):e0120008.
28. Wang M, Zheng Y, Mediavilla JR, et al. Hospital Dissemination of *tst-I*-Positive Clonal Complex 5 (CC5) Methicillin-Resistant *Staphylococcus aureus*. *Front Cell Infect Microbiol.* 2017;7:101.
29. Deurenberg RH, Vink C, Driessen C, et al. Rapid detection of Pantone–Valentine leukocidin from clinical isolates of *Staphylococcus aureus* strains by real-time PCR. *FEMS Microbiol Lett.* 2004;240(2):225–228.